Magic mushroom compound tested to stop chemo nerve pain
NCT ID NCT07227909
First seen Nov 17, 2025 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This Phase 2 trial tests whether psilocybin, the active ingredient in magic mushrooms, can prevent or reduce chemotherapy-induced peripheral neuropathy (nerve damage causing pain and numbness). About 83 adults with breast, colorectal, or head and neck cancer receiving platinum-based or taxane chemotherapy will receive either a 25 mg dose of psilocybin, a 1 mg placebo dose, or standard supportive care. The study aims to see if psilocybin is safe and effective at lowering nerve damage severity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSILOCYBIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin
What this could lead to
If it works, this could offer a new way to prevent or lessen nerve pain from chemotherapy, improving quality of life for cancer patients.
What could go wrong
This is an early Phase 2 trial with only 83 participants, so results may not apply to everyone. Psilocybin can cause temporary psychological effects, and it's unclear if it will outperform placebo or standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.